

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2014/136282 A8

(43) International Publication Date
12 September 2014 (12.09.2014)

(51) International Patent Classification:
C07D 409/06 (2006.01) *A61P 31/10* (2006.01)
A61K 31/4178 (2006.01)

(21) International Application Number:
PCT/JP2013/067952

(22) International Filing Date:
24 June 2013 (24.06.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2013-046593 8 March 2013 (08.03.2013) JP

(71) Applicants: **POLA PHARMA INC.** [JP/JP]; 8-9-5, Nishigotanda, Shinagawa-ku, Tokyo, 1410031 (JP). **NIHON NOHYAKU CO., LTD.** [JP/JP]; 19-8, Kyobashi 1-chome, Chuo-ku, Tokyo, 1048386 (JP).

(72) Inventors: **MASUDA, Takaaki**; c/o POLA PHARMA INC., 560, Kashio-cho, Totsuka-ku, Yokohama-shi, Kanagawa, 2440812 (JP). **MIYATA, Yoshiyuki**; c/o POLA PHARMA INC., 8-9-5, Nishigotanda, Shinagawa-ku, Tokyo, 1410031 (JP). **KANEDA, Hideo**; c/o NIHON NOHYAKU CO., LTD., 19-8, Kyobashi 1-chome, Chuo-ku, Tokyo, 1048386 (JP).

(74) Agents: **KAWAGUCHI, Yoshiyuki** et al.; Acropolis 21 Building 6th floor, 4-10, Higashi Nihonbashi 3-chome, Chuo-ku, Tokyo, 1030004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:


— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

20 August 2015

(15) Information about Correction:
see Notice of 20 August 2015

(54) Title: CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT



(luliconazole)

(57) Abstract: Means for improving the solubility of luliconazole is provided. A crystal of luliconazole represented by the following formula is provided, wherein the crystal has such a crystal habit that (011) plane is a specific crystal growth plane. The crystal is characterized in that $I_{(011)}$ with respect to a sum total of $I_{(001)}$, $I_{(100)}$, $I_{(10-1)}$, $I_{(011)}$, $I_{(110)}$, $I_{(11-1)}$, $I_{(10-2)}$, $I_{(11-2)}$, $I_{(020)}$, $I_{(021)}$, $I_{(20-2)}$, $I_{(121)}$, $I_{(013)}$, $I_{(11-3)}$, and $I_{(221)}$ is not less than 25%, provided that integrated intensities of diffraction peaks, which correspond to the (001), (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020), (021), (20-2), (121), (013), (11-3), and (221) planes, are designated as $I_{(001)}$, $I_{(100)}$, $I_{(10-1)}$, $I_{(011)}$, $I_{(110)}$, $I_{(11-1)}$, $I_{(10-2)}$, $I_{(11-2)}$, $I_{(020)}$, $I_{(021)}$, $I_{(20-2)}$, $I_{(121)}$, $I_{(013)}$, $I_{(11-3)}$, and $I_{(221)}$ respectively in relation to the diffraction peaks detected in a range of $2\theta = 5$ to 35° in a powder X-ray diffractometry using $\text{CuK}\alpha$ radiation.